Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Alzheimer’s disease is a chronic disease than affects several million Brazilian and Mexican patients. Physicians have a small number of molecules available for the treatment of cognitive/functional deficits associated with the disease, and in both markets there are generics for most drugs available. Drug coverage is different in these countries; while Brazilian patients have access to most drugs through the public sector, the Mexican market has a very important OOP component, and drug coverage varies across the different healthcare programs. New agents will find two markets eager to adopt new technologies, especially those that demonstrate they can change the progression of the disease. However, adoption of new health technologies by each country is made with focus on budget balance, and manufacturers will have to adjust their expectations to each country’s price and reimbursement characteristics. This Access & Reimbursement analysis provides key insights for navigating the AD market in Brazil and Mexico while adapting your brand’s value message to payers and physician needs and expectations in each country.
Decision Resources Group’s Access and Reimbursement module for Alzheimer’s disease in Brazil and Mexico explores the prescribing patterns for current AD therapies; the potential impact of the anticipated arrival of novel therapies; and key national, regional, and institutional market access factors that will shape the use of AD therapies over the next two to three years. This report draws on insights from 103 surveyed physicians and from interviews with 6 payers in Brazil and Mexico, all of whom have influence at the institutional, regional, or national level.
Markets covered: Brazil and Mexico.
Questions Answered in This Report:
Already a Client? Log in to access this report.
Nuno T. Antunes, , is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Nuno holds a in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.